Skip to main content
OpenTrials
Completed

NCT Number: NCT05845736

The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neurocognitive Disorders Aged, 80 and Over Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Dementia Hypertension Mental Disorders Nervous System Diseases Vascular Diseases

Age range

80 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Régional Universitaire de Nancy

Nancy, 54000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • to be 80 years of age
  • with history of hypertension and/or on hypertensive drug(s)

Exclusion criteria

  • legal protection measure.

Treatment and study plan

Antihypertensive Agents

Drug

number of hypertensive drugs

Primary outcomes

  1. number of antihypertensive agents

    Time frame: during inclusion

    among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker

Secondary outcomes

  1. class of antihypertensive medications

    Time frame: during inclusion

    among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker

  2. systolic and diastolic blood pressure

    Time frame: during inclusion

    blood pressure measured with upper arm cuffs

  3. orthostatic hypotension

    Time frame: during inclusion

    a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study

Acronym: TAHOC

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
May 6, 2023
Registry last updated
May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.